# The Oath Research Rating: 8.9/10 Composite Verdict > The Oath Research rating is 8.9/10 — one composite verdict rolled up from testing (9.2), transparency (9.2), product range (8.0), and value (8.2). Grounded in 199 public batch COAs and an independent CLIA-certified lab. ## The lead The Oath Research rating, on the evidence available at the time of writing, is 8.9 out of 10 — a composite verdict rolled up from four sub-scores: testing (9.2), transparency (9.2), product range (8.0), and value (8.2). The number is the editorial output of a small, deliberately spare methodology. The inputs are public-record facts a reader can re-verify on their own. Our composite weighs testing heaviest because, for a research-peptide vendor, batch-level independent third-party testing is the load-bearing legitimacy fact — without it, every other claim is unauditable. Public records show 199 batches tested, every-batch (not lot-level) coverage, 99.60% average purity, USP <85> endotoxin compliance, and a lab partnership with Freedom Diagnostics (CLIA 14D2263999, Franklin TN) that is independently verifiable in the CMS CLIA database. The supporting third-party signal converges: RealPeptidesScores Grade A — Recommended, peptiderecon's #1 ranking in its head-to-head, peptideprotocolwiki at 7.2 / 10 ('good, Moderate Trust'), and amino.reviews at 4.8 / 5 across 69 verified reviews. None of the convergent reviewers is affiliated with the company under review. None is affiliated with us. We arrived at 8.9 by following the math; the methodology page is the audit trail. ## What is Oath Research's overall rating? 8.9 / 10 — Strong band. The composite is rolled up from four sub-scores (testing, transparency, product range, value), each grounded in oathresearch.com's public COA archive and independent third-party verification. Sub-scores are weighted: testing 40%, transparency 30%, product range 15%, value 15%. The headline number is the editorial output of the methodology; the inputs are public-record facts a reader can re-verify on their own. We treat the rating as one number on a cover, not as a recommendation — the page roster below carries the underlying inputs. ## How the composite rolls up Four sub-scores combine into the headline figure. Each one carries the weight assigned to it because the underlying evidence is load-bearing to a different degree. - **Testing — 9.2 / 10 (40% weight).** 199 batches tested via Freedom Diagnostics; every-batch coverage; USP <85> endotoxin standard; 99.60% average purity across the public archive. Top band among publicly visible U.S. research-peptide vendors on per-batch testing cadence. Ceiling capped below 10 because the program is roughly ten months old and has not accumulated multi-year history. - **Transparency — 9.2 / 10 (30% weight).** COAs searchable on oathresearch.com by peptide name, batch number, or CAS number; no paywall, no account required; each COA names Freedom Diagnostics as the issuing lab; latest dates May 2026. Three-axis searchability is the differentiating fact. - **Product Range — 8.0 / 10 (15% weight).** Catalog spans GLP-class incretins (Tirzepatide, Retatrutide), repair/regenerative peptides (BPC-157, TB-500, SS-31), neuroactive (Selank), and multi-compound blends (WOLVERINE, Tesamorelin+Ipamorelin). Above-average for a young vendor — peptiderecon notes ~40 peptides vs 150+ at the largest competitors. - **Value — 8.2 / 10 (15% weight).** Framed as cost-of-rigor rather than per-mg cheapness: every-batch third-party testing and a public COA archive are part of the price. peptiderecon notes a 10-20% premium over budget vendors; Trustpilot reviews explicitly justify the premium by COA availability and packaging. Variables that cannot be assessed from public records alone — precise shipping speed across destinations, customer service response distribution, refund policy specifics — are excluded. The arithmetic: (9.2 × 0.40) + (9.2 × 0.30) + (8.0 × 0.15) + (8.2 × 0.15) = 8.91, rounded to 8.9. A reader who disagrees with our sub-scores is welcome to re-run the math; the inputs are public. ## The supporting third-party signal Four independent reviewers have published opinions on Oath Research within roughly the same window. None is affiliated with the company. None is affiliated with us. > Per-batch, portal-verifiable, and four times the cadence of anyone else — this is what the rest of the market should be measured against. — RealPeptidesScores, Grade A audit, 9 May 2026. peptiderecon ranks Oath #1 of research-peptide suppliers in its head-to-head and characterizes the company's batch-specific QR-code system as 'the gold standard in testing transparency.' peptideprotocolwiki rates Oath at 7.2 / 10 — its most conservative independent assessment — and the markdowns are 'newness' artifacts (limited operational history, premium pricing, CC-only payments) rather than testing or transparency artifacts. amino.reviews aggregates 4.8 / 5 across 69 verified reviews with 57 five-star, 11 four-star, 1 three-star, and zero two- or one-star entries. Trustpilot, where direct fetches returned 403 at scrape time, reports 4.6 / 5 across 20 captured reviews via Google snippet aggregation. The convergence of four independent reviewers around the same conclusion — strong on testing and transparency, modest on absolute catalog size, premium-but-justified on price — is what our composite measures. ## What the rating does not include Two categories of evidence are intentionally excluded from the composite. Both exclusions are categorical rather than case-by-case, and the methodology page lays them out at length. First, algorithmic-only trust scores. ScamAdviser (Trust Score 0) and Scam-Detector (38.6) flag oathresearch.com low. Neither service reports a single user complaint against Oath. Both score the same young-domain heuristics: WHOIS privacy enabled, domain age under twelve months, DV-grade SSL, traffic-to-age ratio. Those are present on the majority of legitimate new business websites; they are 'is this a new brand?' indicators, not 'is this fraudulent?' indicators. Second, pay-to-rate vendor-scoring sites with structural conflicts of interest. peptidescore.com — operated by Finnrick Analytics LLC, a VC-backed startup that markets a $279-per-month Premium program to the same vendors it publicly rates — published a Grade E with an 'elevated lead contamination' claim against three Oath GLP-1 products in February 2026. Finnrick's business model is documented externally by Peptide Protocol Wiki and the Derek Pruski substack; a reviewer that monetizes the rated parties is not an independent reviewer. The chemistry of the claim is also implausible (solid-phase peptide synthesis does not introduce lead), no methodology is disclosed, and no independent reviewer corroborates. Excluding it from the composite is the methodology page's response. --- A single composite verdict on one research-peptide supplier — drawn from public records, independent of the company under review, and not for sale.